INTRODUCTION
============

Gastric cancer (or stomach cancer) is a disease in which malignant (cancer) cells develop from the lining of the stomach \[[@B1]\]. It remains a major health problem worldwide, and may spread from the stomach to other parts of the body, particularly the liver, lung, bone, lining of the abdomen and lymph nodes \[[@B2],[@B3]\]. Gastric cancer is the fifth leading cause of cancer and the third leading cause of death worldwide making up 7% of cases and 9% of deaths \[[@B4]\]. According to the cancer statistics, there are approximately 26370 estimated new cases and 10730 estimated deaths in the United States in the year 2016 \[[@B5]\]. Infection with bacteria called *Helicobacter pylori* is a major cause of gastric cancer \[[@B6]\], and other risk factors include gender, cigarette smoking, atrophic gastritis and partial gastrectomy \[[@B7],[@B8]\]. Up to now, gastric cancer remains a major diagnostic and therapeutic challenge \[[@B9],[@B10]\]. The diagnosis is based on conventional white light endoscopy findings, and the prognosis depends on its stage \[[@B11]\]. Surgical resection is the only treatment modality that is potentially curative, but the majority of patients still relapse following resection \[[@B12]\]. In addition, treatment of advanced gastric cancer is controversial and there is no standard regimen for first- or second-line chemotherapy (CT) \[[@B13]\]. Detection of this disease in its early stage is helpful to improve the treatment outcome. Therefore, identifying some biomarkers associated with gastric cancer susceptibility can be used in predicting this disease and guiding the therapeutic strategies.

The development of gastric cancer is a complex and multistep process \[[@B14]\], and the mechanism under this disease is still relatively unknown. A small number of patients may have a genetic predisposition syndrome, and the total number of genome alterations was estimated at 4.18 for gastric cancer \[[@B15]\]. It is characterized by genomic instability that could be either microsatellite instability or chromosomal instability \[[@B16]\], involving multiple genetic and epigenetic alterations in oncogenes, tumour suppressor genes, DNA repair genes, cell-cycle regulators and signalling molecules \[[@B17],[@B18]\]. Thymidylate synthase (TS) gene, located on chromosome 18p11.32, is the critical rate-limiting enzyme in the *de novo* synthesis of dTMP from deoxyuridine monophosphate (dUMP), which is required for DNA synthesis and repair \[[@B19]\]. It is a target for major chemotherapeutic drugs, and its expression is associated with tumour aggressiveness and poor prognosis \[[@B20]\]. In patients with advanced gastric cancer, TS has been identified as a prognostic marker, and high TS expression is associated with worse overall survival \[[@B21]\]. Several polymorphisms in the TS UTRs, which may influence TS mRNA transcription, message stability or protein expression, have been identified \[[@B22]\]. Two functionally important and ethnically diverse polymorphisms are the most extensively studied: TS enhancer region (TSER), a tandem-repeat polymorphism, which contains triple (3R) or double (2R) repeats of a 28-bp sequence in TS 5′-untranslated enhanced region, may be involved in modulation of TS mRNA expression \[[@B23]\]; and a 6-bp ins/del polymorphism on the 3′-UTR (position TS1494, del6 or ins6), which may influence mRNA stability \[[@B24]\]. The presence of the 3R compared with 2R 28-bp repeat sequence has been shown to enhance mRNA transcription and protein expression in *in vitro* and *in vivo* studies \[[@B25]\].

Although several molecular epidemiological studies were conducted to investigate the association between these two TS polymorphisms and gastric cancer risk. However, the results from different studies are divergent to some extent. Moreover, there is a marked geographical variation, with the highest rates reported in East Asia, South America and Eastern Europe and the lowest rates in the United States and Western Europe \[[@B26],[@B27]\]. Therefore, we conducted this meta-analysis to clarify this issue and to obtain a more precise estimation of the relationship between TS polymorphisms and gastric cancer susceptibility.

MATERIALS AND METHODS
=====================

Study identification
--------------------

We searched the electronic databases of Chinese language (CNKI and Wanfang) and English language (PubMed, Emabase and Medline) to retrieve relevant articles published between January 2000 and 2016. The MeSH terms: "gastric cancer or gastric carcinoma or stomach cancer", "thymidylate synthase or TS gene" and "polymorphism or variant" as well as their combinations were used as the searching words. The corresponding Chinese version was used in the Chinese databases. References of related articles were manually searched. When the same authors or laboratories reported this issue on the same population, only the recent full-text articles were included.

Inclusion criteria
------------------

The included studies must meet the following criteria: (1) case-control studies evaluating the effect of TS 5′-UTR and 3′-UTR polymorphisms in gastric cancer risk; (2) the diagnosis of gastric cancer should be made from gastroscopy or surgical biopsy reviewed by an experienced pathologist, and histology should be reported according to the World Health Organization criteria \[[@B28]\]; (3) controls should be unrelated, ethnically matched, healthy individuals; (4) the results were presented in odds ratio (OR) with its 95% corresponding confidence interval (CI); and (5) genotype information in patients and controls were available to extract.

Data extraction
---------------

Two authors independently assessed the information of each included study. Any disagreement was resolved by discussion with a third expert. Each item should be able to reach a final consensus. The following information was extracted from each article: first author, published year, country, mean age, sample size, genotyping methods, genotype distribution and Hardy--Weinberg equilibrium (HWE) in controls.

Statistical analysis
--------------------

The association between TS polymorphisms and gastric cancer risk was measured by pooled OR with 95% CI. The significance of the pooled OR was determined by the *Z*-test, and a *P* value less than 0.05 was considered significant. The allelic model (M compared with m), homozygote model (MM compared with mm), heterozygote model (Mm compared with mm), dominant model (MM+Mm compared with mm) and recessive model (MM compared with Mm+mm) were calculated. The *I*^2^ test and the Q-statistic test were used to determine the between-study heterogeneity. The fixed-effect model was used when the effects were assumed to be homogeneous (a *P*-value more than 0.10 for the Q-test and *I*^2^ less than 50% for the *I*^2^ test), otherwise, the random-effect model was employed. Funnel plot asymmetry was used to assess the publication bias. Analyses were performed using the software Review Manager 5.3 (Oxford). All *P*-values were two-sided.

RESULTS
=======

Characteristics of eligible studies
-----------------------------------

Using the combined search, we first identified 185 relevant references. After applying the inclusion criteria, 13 studies were finally screened out into this meta-analysis, including 2382 gastric cancer patients and 3171 healthy controls. [Figure 1](#F1){ref-type="fig"} represents the searching process. The 13 studies (one was written in Chinese language \[[@B29]\] and twelve in English language \[[@B30]--[@B41]\]) were performed in six countries (China, Korea, Tunisia, Turkey, U.S.A. and Italy). Nine case-control studies were from Asian population, three studies were from Caucasian population, whereas only one study was from African population. The sample size ranged from 86 to 810. Polymorphisms of TS gene were measured by the PCR-restriction fragment length polymorphism (PCR-RFLP). The genotype distribution in controls was in accordance with HWE except studies conducted by Gao et al. \[[@B31]\], Baroudi et al. \[[@B39]\] and Sumen et al. \[[@B41]\]. The detailed characteristics of included studies were summarized in [Table 1](#T1){ref-type="table"}. The information of alleles and genotypes of TS 5′-UTR and 3′-UTR polymorphisms was presented in [Table 2.](#T2){ref-type="table"}
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###### Main characteristics of included studies in this meta-analysis

--, not available

                                  Mean age        Sample size      Genotyping         
  -------------- ------ --------- --------------- ---------------- ------------ ----- ----------
  Gao, C.M.      2004   China     36--81          36--81           155          223   PCR-RFLP
  Graziano, F.   2004   Italy     59 (30--83)     58 (33--77)      134          139   PCR-RFLP
  Zhang, J.H.    2004   China     55.0 (105)      51.3 (10.7)      233          348   PCR-RFLP
  Tan, W.        2005   China     --              --               231          492   PCR-RFLP
  Wang, L.D.     2005   China     58 (40--80)     56 (46--76)      129          315   PCR-RFLP
  Zhang, Z.D.    2005   China     58.7 (9.7)      58.1 (10.6)      322          337   PCR-RFLP
  Yang, L.       2008   China     --              --               60           170   PCR
  Jung, H.       2010   Korea     59.3 (12.4)     45.8 (16.0)      300          100   PCR
  Yim, D.J.      2010   Korea     58.26 (12.75)   57.18 (12.65)    318          280   PCR-RFLP
  Baroudi, O.    2014   Tunisia   56 (30--70)     47.02 (20--80)   52           88    PCR-RFLP
  Pan, X.        2014   China     22--76          18--55           31           200   PCR-RFLP
  Sumen, I.C.    2014   Turkey    59 (37--79)     53 (25--75)      38           48    PCR-RFLP
  Shen, R.       2015   U.S.A.    59.7 (12.7)     59.1 (11.2)      379          431   PCR-RFLP

###### Alleles and genotypes of TS 5′- and 3′-UTR polymorphisms in this meta-analysis

  First author 5′-UTR   Cases           Controls                                                                                                                    
  --------------------- --------------- --------------- --------------- ---------- ---------- --------------- --------------- --------------- ---------- ---------- -------
  Graziano, F.          38              76              18              152        112        31              74              31              136        136        0.303
  Zhang, J.H.           148             76              8               372        92         223             107             13              553        133        0.97
  Tan, W.               157             60              14              374        88         337             137             18              811        173        0.385
  Wang, L.D.            81              39              8               201        55         201             108             6               510        120        0.139
  Zhang, Z.D.           217             101             19              535        139        203             107             12              513        131        0.649
  Yang, L.              31              26              3               88         32         103             54              8               260        70         0.789
  Jung, H.              199             91              10              489        111        60              30              10              150        50         0.135
  Yim, D.J.             211             89              18              511        125        194             79              7               467        93         0.755
  Baroudi, O.           18              8               26              44         60         26              4               58              56         120        0.000
  Pan, X.               20              8               3               48         14         146             48              6               340        60         0.405
  Sumen, I.C.           7               18              13              32         44         9               6               33              24         72         0.000
  **3′-UTR**            **ins6/ins6**   **ins6/del6**   **del6/del6**   **ins6**   **del6**   **ins6/ins6**   **ins6/del6**   **del6/del6**   **ins6**   **del6**   
  Gao, C.M.             10              80              65              100        210        18              121             84              157        289        0.018
  Graziano, F.          39              73              22              151        117        62              59              18              183        95         0.505
  Zhang, J.H.           24              105             104             153        313        34              155             159             223        473        0.671
  Zhang, Z.D.           53              143             141             249        425        30              139             153             199        445        0.846
  Yim, D.J.             29              130             159             188        448        19              121             140             159        401        0.294
  Pan, X.               3               10              18              16         46         22              90              88              134        266        0.888
  Shen, R.              144             163             72              451        307        192             190             49              574        288        0.847

###### Summary of pooled ORs with CI of TS 5′- and 3′-UTR polymorphisms in gastric cancer risk in this meta-analysis

*N*, number of included studies; F, the fixed-effect model; R, the random-effect model.

                                                                           Test of association   Test of heterogeneity                    
  -------- ------------ --------------------------------------------- ---- --------------------- ----------------------- ---------- ----- ---
  5′-UTR   Total        2R compared with 3R                           11   0.97 (0.81, 1.14)     0.68                    0.01       55%   R
                        2R/2R compared with 3R/3R                          1.08 (0.68, 1.71)     0.76                    0.003      63%   R
                        3R/2R compared with 3R/3R                          1.01 (0.88, 1.17)     0.86                    0.43       2%    F
                        2R/2R+3R/2R compared with 3R/3R                    1.01 (0.88, 1.15)     0.90                    0.74       0%    F
                        2R/2R compared with 3R/2R+3R/3R                    0.98 (0.58, 1.63)     0.93                    \<0.0001   73%   R
           Asians       2R compared with 3R                           8    1.08 (0.95, 1.21)     0.24                    0.23       25%   F
                        2R/2R compared with 3R/3R                          1.42 (0.83, 2.42)     0.19                    0.02       59%   R
                        3R/2R compared with 3R/3R                          0.99 (0.86, 1.15)     0.94                    0.83       0%    F
                        2R/2R+3R/2R compared with 3R/3R                    1.04 (0.90, 1.20)     0.59                    0.67       0%    F
                        2R/2R compared with 3R/2R+3R/3R                    1.41 (0.83, 2.40)     0.21                    0.01       60%   R
           Non-Asians   2R compared with 3R                           3    0.66 (0.51, 0.85)     0.001                   0.044      0%    F
                        2R/2R compared with 3R/3R                          0.54 (0.34, 0.88)     0.01                    0.84       0%    F
                        3R/2R compared with 3R/3R                          1.82 (0.62, 5.30)     0.27                    0.05       67%   R
                        2R/2R+3R/2R compared with 3R/3R                    0.78 (0.52, 1.18)     0.24                    0.87       0%    F
                        2R/2R compared with 3R/2R+3R/3R                    0.44 (0.29, 0.67)     0.0001                  0.31       16%   F
  3′-UTR                del6 compared with ins6                       7    1.09 (0.90, 1.33)     0.37                    0.003      70%   R
                        del6/del6 compared with ins6/ins6                  1.12 (0.72, 1.76)     0.61                    0.002      70%   R
                        Ins6/del6 compared with ins6/ins6                  1.00 (0.73, 1.38)     0.98                    0.05       53%   R
                        del6/del6+del6/ins6 compared with ins6/ins6        1.05 (0.74, 1.49)     0.80                    0.009      65%   R
                        del6/del6 compared with del6/ins6+ins6/ins6        1.14 (0.90, 1.45)     0.27                    0.03       56%   R
           Asians       del6 compared with ins6                       5    0.94 (0.83, 1.06)     0.31                    0.15       40%   F
                        del6/del6 compared with ins6/ins6                  0.78 (0.59, 1.04)     0.10                    0.23       29%   F
                        ins6/del6 compared with ins6/ins6                  0.77 (0.57, 1.03)     0.08                    0.58       0%    F
                        del6/del6+del6/ins6 compared with ins6/ins6        0.77 (0.59, 1.02)     0.07                    0.36       8%    F
                        del6/del6 compared with del6/ins6+ins6/ins6        0.98 (0.83, 1.15)     0.79                    0.29       19%   F
           Caucasians   del6 compared with ins6                       2    1.39 (1.17, 1.66)     0.0002                  0.64       0%    F
                        del6/del6 compared with ins6/ins6                  1.96 (1.35, 2.82)     0.0003                  0.98       0%    F
                        ins6/del6 compared with ins6/ins6                  1.43 (0.85, 2.42)     0.18                    0.08       67%   R
                        del6/del6+del6/ins6 compared with ins6/ins6        1.44 (1.13, 1.85)     0.003                   0.17       47%   F
                        del6/del6 compared with del6/ins6+ins6/ins6        1.68 (1.20, 2.36)     0.003                   0.41       0%    F

Correlation of TS 5′-UTR 2R/3R polymorphism in gastric cancer susceptibility
----------------------------------------------------------------------------

The results of this meta-analysis were listed in [Table 3](#T3){ref-type="table"}. Eleven articles including 1859 patients and 2489 controls were eligible for pooling OR data. The between-study heterogeneity was calculated, the fixed-effect model was used in the heterozygote model and the dominant model, whereas the random-effect model was performed in other comparison models. Analyses of the 11 relevant studies showed that there was no obvious association between TS 5′-UTR 2R/3R polymorphism and gastric cancer risk under any genetic models as shown in [Figure 2.](#F2){ref-type="fig"}

![Meta-analysis of the correlation between TS 5′-UTR polymorphism and gastric cancer susceptibility under the allelic model (**A**), homozygote model (**B**), heterozygote model (**C**), dominant model (**D**) and recessive model (**E**)](bsr036e429fig2){#F2}

Subgroup analysis was conducted based on ethnicity including Asian population and non-Asian population (Caucasian and African). Our result detected that 2R of TS 5′-untranslated enhanced region contributed to gastric cancer risk in non-Asian population under the allelic model (2R compared with 3R: OR=0.66, 95% CI=0.51--0.85, *P*=0.001), homozygote model (2R/2R compared with 3R/3R: OR=0.54, 95% CI=0.34--0.88, *P*=0.01) and recessive model (2R/2R compared with 3R/2R+3R/3R: OR=0.44, 95% CI=0.29--0.67, *P*=0.0001) in the fixed-effect model as shown in [Figure 3](#F3){ref-type="fig"}. For the Asian population, there was no obvious association between TS 5′-UTR 2R/3R polymorphism and gastric cancer susceptibility under the five comparison models ([Table 3](#T3){ref-type="table"}).

![Forest plot of TS 5′-UTR variant and gastric cancer risk under the allelic model (**A**), homologous model (**B**), and recessive effect (**C**) in the fixed-effect model in non-Asian populations (Caucasian and African)](bsr036e429fig3){#F3}

Correlation of TS 3′-UTR del6/ins6 polymorphism in gastric cancer susceptibility
--------------------------------------------------------------------------------

Seven articles contained 1587 gastric cancer patients and 1943 controls. Significant heterogeneity among included studies was detected, and the random-effect model was employed. Our result found that the TS 3′-UTR del6/ins6 variant was not associated with gastric cancer risk under any genetic models ([Table 3](#T3){ref-type="table"}). Subgroup analysis by ethnicity showed that TS 3′-UTR del6/ins6 variant was significantly related with gastric cancer risk under the allelic model (del6 compared with ins6: OR=1.39, 95% CI=1.17--1.66, *P*=0.0002), homozygote model (del6/del6 compared with ins6/ins6: OR=1.96, 95% CI=1.35--2.82, *P*=0.0003), dominant model (del6/del6  + del6/ins6 compared with ins6/ins6: OR=1.44, 95% CI=1.13--1.85, *P*=0.003) and recessive model (del6/del6 compared with del6/ins6+ins6/ins6: OR=1.68, 95% CI=1.20--2.36, *P*=0.003) in Caucasian population as shown in [Figure 4](#F4){ref-type="fig"}. No correlation was detected between this genetic variant and gastric cancer risk in Asian population.

![Forest plot of pooled OR with 95% CI for TS 3′-UTR polymorphism and gastric cancer risk under the allelic model (**A**), homozygote model (**B**), dominant model (**C**) and recessive model (**D**) in Caucasian population](bsr036e429fig4){#F4}

Sensitivity analysis and publication bias
-----------------------------------------

We conducted the sensitivity analysis to verify whether our results were affected by each included study. Our result indicated that single study could not influence the pooled OR qualitatively, suggesting that the result was stable. Funnel plot was used to assess publication bias, and the shape of the funnel plots was symmetrical, indicating no publication bias in this meta-analysis as shown in [Figure 5.](#F5){ref-type="fig"}

![Funnel plot of TS 5′-UTR polymorphism in gastric cancer risk under the heterogeneous model](bsr036e429fig5){#F5}

DISCUSSION
==========

In this meta-analysis, we totally screened out 13 relevant articles concerning TS 5′-UTR 2R/3R and 3′-UTR del6/ins6 polymorphisms. Our result found that both these two variants were not associated with gastric cancer risk. Subgroup analysis by ethnicity showed that 2R of TS 5′-UTR 2R/3R and del6 of TS 3′-UTR del6/ins6 variants were associated with increased risk of gastric cancer risk in Caucasian population. Our result was not consistent with three previous meta-analyses: one was conducted by Yang et al. \[[@B42]\] that contained six included articles and suggested that 2R of TYMS 5′-UTR 2R/3R contributed to gastric cancer risk in the Asian population, one was conducted by Lu et al. \[[@B43]\] that suggested that the 3R variant of TS 5\'-untranslated enhanced region 2R/3R polymorphism contributed to gastric cancer risk in the Caucasian population, and the last one was conducted by Zhuang et al. \[[@B44]\] that showed that polymorphisms in the 5′-UTR and 3′-UTR of the TS gene might be associated with gastric cancer susceptibility.

Gastric cancer is a prevalent yet heterogeneous disease. The role of genetic predisposition to gastric cancer has been suggested by epidemiological studies \[[@B45]\]. Individual genetic susceptibility may be critical in a variety of processes relevant to the tumorigenesis of gastric cancer, such as the cell apoptotic pathway, cell proliferation ability, the intrinsic variability of DNA repair processes, the inflammatory response and the functioning of carcinogen detoxification and antioxidant protection \[[@B46]\]. Identifying the relevant genes can be used as a tool to search for genetic variations of the disease\'s genes and susceptibility, thus to increase understanding of this disease\'s mechanism \[[@B47]\].

The folate metabolic pathway is involved in the synthesis and methylation of DNA, and low folate levels were shown to be associated with an increased risk of gastric cancer \[[@B48]\]. TS is one of the key enzymes that involved in the folate metabolism. Variants of TS gene differ not only biologically but also functionally in their ability to alter TYMS activation on folate metabolism \[[@B49]\]. Furthermore, TS holds promise as a prognostic biomarker because of its role as the molecular target of 5-FU, a commonly used chemotherapeutic agent in gastric cancer \[[@B50]\]. High TS gene expression in tumours was associated with enhanced benefit from post-operative adjuvant S-1 treatment in gastric cancer \[[@B51]\], and might predict drug resistance and adverse prognosis in patients with advanced stages treated with FU-based CT \[[@B52]\]. TS expression was also associated with CT response, progression-free survival and overall survival in advanced gastric cancer patients treated with capecitabine alone CT \[[@B53]\]. Moreover, TS mRNA level in plasma can mirror tumour TS mRNA level, and both of them can be used to predict raltitrexed sensitivity in gastric cancer \[[@B54]\].

Several studies have identified the role of TS polymorphisms in gastric cancer risk; however, the results still remain inconclusive. Shen et al. \[[@B40]\] found that the del6/del6 genotype of TS 3′-UTR was associated with significantly increased gastric cancer risk, Sumen et al. \[[@B41]\] suggested that 3R allele, 2R/3R and 3R/3R genotypes were risk factors for gastric cancer, whereas Araújo et al. \[[@B55]\] did not obtain a significant relationship between TS 5′-UTR 2R/3R and 3′-UTR del6/ins6 polymorphisms and gastric cancer susceptibility. Studies have also shown that TS polymorphisms might be associated with other cancers' risks such as colon cancer \[[@B56]\], lung cancer \[[@B57]\] and oral squamous cell carcinoma \[[@B58]\]. In addition, genetic variation in TS gene may affect carcinogenesis through the regulation of gene expression, the status of the dNTP pool and drug sensitivity. Gao et al. \[[@B59]\] first reported that TS 3′-UTR ins6/ins6 genotype could predict the poor survival of advanced gastric cancer patients treated with capecitabine plus paclitaxel. Huang et al. \[[@B60]\] found that the polymorphisms of TS 3′-UTR del6/ins6 might be potential prognostic factor in gastric cancer patients treated with 5-FU-based adjuvant CT. Kim et al. \[[@B61]\] demonstrated that TS genotyping could be of help in predicting toxicity in oral fluoropyrimidine-based CT in advanced gastric cancer patients.

Several limitations were presented in this meta-analysis. Firstly, the number of included studies for subgroup analysis was small, which might affect the accuracy of our result. Secondly, the stages of patients with gastric cancer could not be extracted from the included articles due to the lack of sufficient data. Thirdly, gene--gene interaction should be addressed in the future meta-analysis for the study of combined polymorphisms, instead of single low-penetrance variations in susceptibility that may lead to a high-risk classification for a specific population \[[@B62]\]. Lastly, other factors, such as gender, smoking and drinking should be considered as well in the future researches.

In conclusions, our meta-analysis suggested that 2R of TS 5′-UTR 2R/3R and del6 of TS 3′-UTR del6/ins6 might contribute to gastric cancer risk in the Caucasian population. However, future large-scale studies with more ethnicities are still needed to further investigate this association.
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